Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

p://www.amgen.com/">www.amgen.com for full prescribing information.

Denosumab is also marketed as Prolia™ in other indications.

D-CARE: XGEVA Adjuvant Breast Cancer Study Enrolling Patients NowAs part of Amgen's continued commitment to improving outcomes for people living with breast cancer, XGEVA is also being investigated as adjuvant treatment for women with early-stage breast cancer who are at high-risk of disease recurrence. A large Phase 3 study known as D-CARE is comparing the treatment effect of denosumab with that of placebo on prolonging bone metastasis-free survival (BMFS), and on prolonging disease-free survival (DFS). The trial will enroll 4,500 patients. For more information, please visit www.clinicaltrials.gov (identifier number 01077154).

XGEVA FIRST STEP™ COUPON PROGRAMAmgen is committed to supporting patient access to important medicines through innovative programs including our newly established commercial co-pay program for XGEVA, the Safety Net Foundation, which provides free Amgen products to uninsured patients who qualify, and financial support to independent third party co-pay foundations. The XGEVA FIRST STEP™ Coupon Program is a landmark program among oncology commercial co-pay programs, as it is the first program under the medical benefit with no income eligibility requirement.  The program offers a coupon to eligible patients that can be used to help meet their deductible, co-insurance, and/or co-payment requirements under the medical benefit for XGEVA. For more information, please visit http://www.amgenfirststep.com/.

XGEVA Regulatory StatusXGEVA was approved by the FDA for the prevention of SREs in patients with bone metastases from solid tumors on Nov. 18, 2010. XGEVA is not indicated to prevent SREs in patients with multiple myeloma. Administered as a single 120 mg subcutaneo
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) ... novel investigational drug for cancer, is designed for injection ... effects. Its oncology focus is on melanoma, breast cancer ... 2 trials of PV-10 as a therapy for metastatic ... atopic dermatitis and psoriasis. This summer, ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 24, 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... manufacturer and marketer of orthopedic implants in China, today announced ... First Quarter 2012 Highlights , ... by 21.6% year-over-year to RMB82.7 million from RMB68.0 ...
... Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products for the treatment of patients with voiding dysfunctions, ... expand its commitment to using the Company,s neuromodulation technology ... begin development of an implantable tibial nerve stimulator for ...
Cached Medicine Technology:China Kanghui Holdings Reports First Quarter 2012 Financial Results 2China Kanghui Holdings Reports First Quarter 2012 Financial Results 3China Kanghui Holdings Reports First Quarter 2012 Financial Results 4China Kanghui Holdings Reports First Quarter 2012 Financial Results 5China Kanghui Holdings Reports First Quarter 2012 Financial Results 6China Kanghui Holdings Reports First Quarter 2012 Financial Results 7China Kanghui Holdings Reports First Quarter 2012 Financial Results 8China Kanghui Holdings Reports First Quarter 2012 Financial Results 9China Kanghui Holdings Reports First Quarter 2012 Financial Results 10China Kanghui Holdings Reports First Quarter 2012 Financial Results 11China Kanghui Holdings Reports First Quarter 2012 Financial Results 12China Kanghui Holdings Reports First Quarter 2012 Financial Results 13Uroplasty Announces Product Development and New Clinical Trial Initiatives 2Uroplasty Announces Product Development and New Clinical Trial Initiatives 3Uroplasty Announces Product Development and New Clinical Trial Initiatives 4
(Date:10/22/2014)... Best Cheap Hosting USA is among the ... has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is ... around the world. , “iPower is one of the ... providing various kinds of useful products for new and ... excellent customer service and a number of features which ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... ... has joined the Climate Savers Computing Initiative, a non-profit organization dedicated to reducing computer power ... ... that it has joined the Climate Savers Computing Initiative, a non-profit organization dedicated to reducing ...
... ... few short months ago the Pionetics Corporation introduced the LINX® Water Treatment System, the smartest ... so well, the company just shipped its 1,000th unit., , ... San Carlos, CA (PRWEB) June 25, 2010 -- Just a ...
... red wine, grapes, blueberries, peanuts and other plants ... to vision researchers at Washington University School of Medicine ... preserving vision in blinding eye diseases such as diabetic ... blindness in Americans over 50. The formation of ...
... ... Bob Adams speaks out for drug awareness and education. , , ... Los Angeles (Vocus) June 26, 2010 -- Addressing a ... Church of Scientology Community Relations Specialist, Bob Adams asked the youth who among them ...
... , ... announce that Asia Research News 2010 is now available online and in print. , ... (PRWebUK) June 24, 2010 -- We ... online at Asia Research News , , , , ,The magazine features interesting on-going ...
... experienced the strong heartbeat that accompanies emotions such as fear ... emotions be used to combat heart failure? Results of a ... present a strong case. In the ... that two experimental drugs have the potential to restore pumping ...
Cached Medicine News:Health News:Be Green Canada Joins Computing Initiative 2Health News:Be Green Canada Joins Computing Initiative 3Health News:Pionetics Ships its 1,000th LINX Drinking Water System 2Health News:Pionetics Ships its 1,000th LINX Drinking Water System 3Health News:Ingredient in red wine may prevent some blinding diseases 2Health News:Ingredient in red wine may prevent some blinding diseases 3Health News:Young Athletes Warned of Drug Dangers 2Health News:Young Athletes Warned of Drug Dangers 3Health News:Asia Research News 2010 2Health News:Asia Research News 2010 3Health News:Targeting flight-or-fight hormone response to combat heart failure 2Health News:Targeting flight-or-fight hormone response to combat heart failure 3